{
    "id": "be9ce233f3",
    "abstract": [],
    "body_text": [
        {
            "text": "The ultimate goal of treating glaucoma is to reduce intraocular pressure (IOP) and to preserve the visual field. ",
            "section": "Introduction"
        },
        {
            "text": "Initial glaucoma therapies generally consist of prostaglandin analog monotherapy. ",
            "section": "Introduction"
        },
        {
            "text": "1,2 However, when inadequate IOP control with a single analog occurs, a different monotherapy agent or an additional medication must be used. ",
            "section": "Introduction",
            "ref_spans": [
                {
                    "start": 0,
                    "end": 2,
                    "type": "bibr",
                    "ref_id": "b0",
                    "text": "1,"
                },
                {
                    "start": 2,
                    "end": 3,
                    "type": "bibr",
                    "ref_id": "b1",
                    "text": "2"
                }
            ]
        },
        {
            "text": "3 Multiple medications increase the number of eye drops instilled, which can lead to poor patient adherence. ",
            "section": "Introduction",
            "ref_spans": [
                {
                    "start": 0,
                    "end": 1,
                    "type": "bibr",
                    "ref_id": "b2",
                    "text": "3"
                }
            ]
        },
        {
            "text": "Therefore, a fixed-combination eye drop that contains two different medications is recommended. ",
            "section": "Introduction"
        },
        {
            "text": "Several fixed-combination eye drops have been approved for use in Japan and have been available since 2011. ",
            "section": "Introduction"
        },
        {
            "text": "These include fixed combinations of a prostaglandin analog and timolol (latanoprost/timolol [Xalacom \u00ae , Pfizer, Inc., New York, NY, USA], travoprost/timolol [DuoTrav \u00ae , Alcon Laboratories Inc., Fort Worth, TX, USA]) and a fixed combination of a Correspondence: Kenji Inoue Inouye Eye Hospital, 4-3 Kanda-Surugadai, Chiyoda-ku, Tokyo 101-0062, Japan Tel +81 03 3295 0911 Fax +81 03 3295 0917 Email inoue-k@inouye-eye.or.jp This article was published in the following Dove Press journal: Clinical Ophthalmology 9 April 2015 Number of times this article has been viewed carbonic anhydrase inhibitor and timolol ( dorzolamide/ timolol [Cosopt \u00ae , Merck & Co., Inc., Whitehouse Station, NJ, USA]). ",
            "section": "Introduction"
        },
        {
            "text": "In November 2013, a fixed-combination eye drop containing brinzolamide and timolol (Azarga, Alcon Laboratories, Inc.) was approved for use in Japan. ",
            "section": "Introduction"
        },
        {
            "text": "This brinzolamide/timolol fixed-combination (BTFC) eye drop was shown to be extremely effective in reducing IOP in Japanese glaucoma patients. ",
            "section": "Introduction"
        },
        {
            "text": "[4][5][6] However, dorzolamide/ timolol fixed-combination (DTFC) eye drops have been shown to be better for reducing IOP reduction than both latanoprost 7 and brimonidine/timolol fixed-combination drops. ",
            "section": "Introduction",
            "ref_spans": [
                {
                    "start": 0,
                    "end": 3,
                    "type": "bibr",
                    "ref_id": "b3",
                    "text": "[4]"
                },
                {
                    "start": 3,
                    "end": 6,
                    "type": "bibr",
                    "ref_id": "b4",
                    "text": "[5]"
                },
                {
                    "start": 6,
                    "end": 9,
                    "type": "bibr",
                    "ref_id": "b5",
                    "text": "[6]"
                },
                {
                    "start": 153,
                    "end": 154,
                    "type": "bibr",
                    "ref_id": "b6",
                    "text": "7"
                }
            ]
        },
        {
            "text": "8 It has been shown that switching patients from a DTFC eye drop to a BTFC eye drop is both safe and effective in reducing IOP, 9-11 but this has not been specifically examined in a Japanese population.",
            "section": "Introduction",
            "ref_spans": [
                {
                    "start": 0,
                    "end": 1,
                    "type": "bibr",
                    "ref_id": "b7",
                    "text": "8"
                }
            ]
        },
        {
            "text": "Here, we prospectively evaluate IOP reduction, patient comfort, and treatment safety when switching from a DTFC eye drop to a BTFC eyed drop in patients with primary openangle glaucoma and ocular hypertension. ",
            "section": "Introduction"
        },
        {
            "text": "Patients were followed for 3 months following the medication switch.",
            "section": "Introduction"
        },
        {
            "text": "primary open-angle glaucoma or ocular hypertension who were using DTFC eye drops at Inouye Eye Hospital were enrolled in this study between November 2013 and August 2014. ",
            "section": "A total of 35 eyes of 35 patients (12 men, 23 women) with"
        },
        {
            "text": "The protocol was approved by the hospital's ethical committee, and all participants provided written informed consent before any study procedure or examination was performed.",
            "section": "A total of 35 eyes of 35 patients (12 men, 23 women) with"
        },
        {
            "text": "Participants discontinued their twice-daily use of DTFC eye drops (Cosopt \u00ae , Merck & Co., Inc.) and immediately switched to a twice-daily use (morning and evening instillation) of BTFC eye drops (Azarga, Alcon Laboratories, Inc.) (twice a day, morning and evening instillation). ",
            "section": "A total of 35 eyes of 35 patients (12 men, 23 women) with"
        },
        {
            "text": "All other topical medication used remained the same. ",
            "section": "A total of 35 eyes of 35 patients (12 men, 23 women) with"
        },
        {
            "text": "When participant were using DTFC eye drops in both eyes, the eye with the higher IOP was selected as the study eye. ",
            "section": "A total of 35 eyes of 35 patients (12 men, 23 women) with"
        },
        {
            "text": "If both eyes had the same IOP, the right eye was selected as the study eye.",
            "section": "A total of 35 eyes of 35 patients (12 men, 23 women) with"
        },
        {
            "text": "The IOP was measured at approximately the same time each visit using a Goldmann tonometer. ",
            "section": "A total of 35 eyes of 35 patients (12 men, 23 women) with"
        },
        {
            "text": "The magnitude of IOP reduction was defined as the IOP 3 months after switching medication minus the IOP at baseline. ",
            "section": "A total of 35 eyes of 35 patients (12 men, 23 women) with"
        },
        {
            "text": "One month after switching medications, participant preference and adherence to BTFC therapy use were evaluated ( Table 1). ",
            "section": "A total of 35 eyes of 35 patients (12 men, 23 women) with",
            "ref_spans": [
                {
                    "start": 113,
                    "end": 120,
                    "type": "table",
                    "ref_id": "tab_0",
                    "text": "Table 1"
                }
            ]
        },
        {
            "text": "Participants were also asked about experiencing specific adverse reactions at each study visit. ",
            "section": "A total of 35 eyes of 35 patients (12 men, 23 women) with"
        },
        {
            "text": "Reasons for participant dropout were also recorded.",
            "section": "A total of 35 eyes of 35 patients (12 men, 23 women) with"
        },
        {
            "text": "All data are presented as mean \u00b1 standard deviation, where applicable. ",
            "section": "Data analyses"
        },
        {
            "text": "Differences in mean IOP at baseline and at 1 and 3 months were analyzed using paired t-tests. ",
            "section": "Data analyses"
        },
        {
            "text": "Commercially available statistical software (SPSS, version 22; SPSS, Inc., Chicago, IL, USA) was used to perform all statistical analyses. ",
            "section": "Data analyses"
        },
        {
            "text": "Statistical significance was defined as P,0.05.",
            "section": "Data analyses"
        },
        {
            "text": "The IOP 1 and 3 months after switching medications was 18.3\u00b14.1 mmHg (n=33 eyes) and 17.8\u00b13.4 mmHg (n=29 eyes), respectively. ",
            "section": "IOP after switching medications"
        },
        {
            "text": "These slight differences from baseline (17.9\u00b12.6 mmHg, n=35 eyes) were not statistically significant (P=0.633, Figure 1). ",
            "section": "IOP after switching medications",
            "ref_spans": [
                {
                    "start": 111,
                    "end": 119,
                    "type": "figure",
                    "text": "Figure 1"
                }
            ]
        },
        {
            "text": "Three months after switching medication, 10 (34.5%) eyes had a decrease in IOP $2 mmHg, 13 (44.8%) eyes had no change in IOP (within 2 mmHg of baseline), and 6 (20.7%) eyes had an increase in IOP $2 mmHg.",
            "section": "IOP after switching medications"
        },
        {
            "text": "Subject comfort and compliance were evaluated 1 month after switching medications. ",
            "section": "Subject compliance and comfort"
        },
        {
            "text": "Two (6.1%) subjects reported missing BTFC drop doses, which was not significantly different than the 2 (6.1%) subjects who missed DTFC drop doses (P=0.999, Table 2). ",
            "section": "Subject compliance and comfort",
            "ref_spans": [
                {
                    "start": 156,
                    "end": 163,
                    "type": "table",
                    "ref_id": "tab_2",
                    "text": "Table 2"
                }
            ]
        },
        {
            "text": "Five (15.2%) subjects reported stinging with BTFC drop use, which was significantly less than the 17 (51.5%) subjects who reported stinging with DTFC drop use (P,0.01). ",
            "section": "Subject compliance and comfort"
        },
        {
            "text": "Thirteen (39.4%) subjects reported blurred vision with DTFC drop use, which was not significantly different than the 14 (42.4%) subjects who reported blurred vision with BTFC drop use (P=0.999). ",
            "section": "Subject compliance and comfort"
        },
        {
            "text": "Figure 2 summarizes the stinging and blurred vision that subjects experienced during BTFC drop use.",
            "section": "Subject compliance and comfort",
            "ref_spans": [
                {
                    "start": 0,
                    "end": 8,
                    "type": "figure",
                    "text": "Figure 2"
                }
            ]
        },
        {
            "text": "A total of 9 (27.3%) participants preferred to use BTFC drops, 11 (33.3%) participants preferred to use DTFC drops, and 13 (39.4%) participants expressed no preference ( Figure 3). ",
            "section": "Subject compliance and comfort",
            "ref_spans": [
                {
                    "start": 168,
                    "end": 178,
                    "type": "figure",
                    "text": "( Figure 3"
                }
            ]
        },
        {
            "text": "Subjects preferred BTFC drops because they had less stinging (n=5 subjects) and better IOP reduction (n=5 subjects). ",
            "section": "Subject compliance and comfort"
        },
        {
            "text": "Subjects preferred DTFC drops because they had less blurred vision (n=7 subjects), less stinging (n=2 subjects), and less discomfort (n=2 subjects).",
            "section": "Subject compliance and comfort"
        },
        {
            "text": "Six (17.1%) participants dropped out of the study before the end of the 3-month study period. ",
            "section": "Subject compliance and comfort"
        },
        {
            "text": "Participants withdrew from the study because of increased IOP (n=2 [ ",
            "section": "Subject compliance and comfort",
            "ref_spans": [
                {
                    "start": 67,
                    "end": 68,
                    "type": "bibr",
                    "text": "["
                }
            ]
        },
        {
            "text": "Several reports on the efficacy of BTFC eye drops in Japanese patients have been published. ",
            "section": "Discussion"
        },
        {
            "text": "[4][5][6] Yoshikawa et al 4 treated 301 patients with primary open-angle glaucoma or ocular hypertension with timolol for 4 weeks. ",
            "section": "Discussion",
            "ref_spans": [
                {
                    "start": 0,
                    "end": 3,
                    "type": "bibr",
                    "ref_id": "b3",
                    "text": "[4]"
                },
                {
                    "start": 3,
                    "end": 6,
                    "type": "bibr",
                    "ref_id": "b4",
                    "text": "[5]"
                },
                {
                    "start": 6,
                    "end": 9,
                    "type": "bibr",
                    "ref_id": "b5",
                    "text": "[6]"
                },
                {
                    "start": 26,
                    "end": 27,
                    "type": "bibr",
                    "ref_id": "b3",
                    "text": "4"
                }
            ]
        },
        {
            "text": "Patients were then divided into two groups, with one group switched to BTFC drops (150 cases) and the other group continuing on timolol drops (151 cases). ",
            "section": "Discussion"
        },
        {
            "text": "Treatment was continued for an additional 8 weeks in both groups. ",
            "section": "Discussion"
        },
        {
            "text": "Eight weeks after group differentiation, IOP in the BTFC group was 3.2 mmHg lower (measured 2 hours after drop instillation) than before the switch. ",
            "section": "Discussion"
        },
        {
            "text": "Adverse reactions experienced were stinging (5%), blurred vision (1%), and hyperemia (1%). ",
            "section": "Discussion"
        },
        {
            "text": "Nagayama et al 5 administered timolol therapy  9 reported what happened after switching from various therapies to BTFC drops. ",
            "section": "Discussion",
            "ref_spans": [
                {
                    "start": 47,
                    "end": 48,
                    "type": "bibr",
                    "ref_id": "b8",
                    "text": "9"
                }
            ]
        },
        {
            "text": "In the 2,937 patients who switched from DTFC drops to BTFC drops, IOP significantly decreased from 18.5\u00b14.1 mmHg to 16.5\u00b13.2 mmHg. ",
            "section": "Discussion"
        },
        {
            "text": "Moreover, IOP was significantly lower in 823 patients who switched from a prostaglandin analog plus DTFC drops (18.3\u00b15.0 mmHg) to a prostaglandin analog plus BTFC drops (16.4\u00b13.9 mmHg). ",
            "section": "Discussion"
        },
        {
            "text": "Auger et al 10 evaluated stinging, blurred vision, eye redness, and abnormal taste in 31 patients who switched from DTFC to BTFC. ",
            "section": "Discussion"
        },
        {
            "text": "Patients using DTFC drops experienced more stinging and patients using BTFC drops experienced more blurred vision. ",
            "section": "Discussion"
        },
        {
            "text": "There were no differences in eye redness and abnormal taste. ",
            "section": "Discussion"
        },
        {
            "text": "Rossi et al 11 investigated tear film breakup time, corneal stinging, and glaucoma symptom scale score 12 in 72 patients switching from DTFC. ",
            "section": "Discussion",
            "ref_spans": [
                {
                    "start": 103,
                    "end": 105,
                    "type": "bibr",
                    "ref_id": "b11",
                    "text": "12"
                }
            ]
        },
        {
            "text": "A significant improvement was reported for all evaluations. ",
            "section": "Discussion"
        },
        {
            "text": "Adverse reactions included blurred vision (4.2%) and dysgeusia (2.7%). ",
            "section": "Discussion"
        },
        {
            "text": "IOP was not affected by switching medications.",
            "section": "Discussion"
        },
        {
            "text": "In our study, no patients used DTFC drops concomitantly with an analog. ",
            "section": "Discussion"
        },
        {
            "text": "We observed no changes in IOP that resulted from switching to a prostaglandin analog plus BTFC drops (n=18 cases). ",
            "section": "Discussion"
        },
        {
            "text": "These results differed from those reported by Lanzl and Raber. ",
            "section": "Discussion"
        },
        {
            "text": "9 However, IOP decreased or increased by $2 mmHg in 55.2% of subjects. ",
            "section": "Discussion"
        },
        {
            "text": "Therefore, we conclude that changes in IOP vary between patients.",
            "section": "Discussion"
        },
        {
            "text": "Our observed efficacy in reducing IOP was not significantly different from a previous report comparing dorzolamide 2.0%/timolol fixed-combination drops with  ",
            "section": "Discussion"
        },
        {
            "text": "Publish your work in this journal BTFC drops. ",
            "section": "Clinical Ophthalmology"
        },
        {
            "text": "13 However, this previous study reported that participants withdrew from the study because of adverse reactions, including discomfort, discharge, and dizziness. ",
            "section": "Clinical Ophthalmology",
            "ref_spans": [
                {
                    "start": 0,
                    "end": 2,
                    "type": "bibr",
                    "ref_id": "b12",
                    "text": "13"
                }
            ]
        },
        {
            "text": "In our study, 14.3% and 40% of participants reported stinging and blurred vision, respectively. ",
            "section": "Clinical Ophthalmology"
        },
        {
            "text": "This was not significantly different than that reported in a previous study (stinging in 42%, blurred vision in 55%). ",
            "section": "Clinical Ophthalmology"
        },
        {
            "text": "10 Moreover, we observed no severe adverse reactions, which is in agreement with past reports. ",
            "section": "Clinical Ophthalmology",
            "ref_spans": [
                {
                    "start": 0,
                    "end": 2,
                    "type": "bibr",
                    "ref_id": "b9",
                    "text": "10"
                }
            ]
        },
        {
            "text": "[4][5][6][9][10][11]13,14 Also in agreement with past reports, 10,13,14 less stinging was reported in the BTFC group than in the DTFC group. ",
            "section": "Clinical Ophthalmology",
            "ref_spans": [
                {
                    "start": 0,
                    "end": 3,
                    "type": "bibr",
                    "ref_id": "b3",
                    "text": "[4]"
                },
                {
                    "start": 3,
                    "end": 6,
                    "type": "bibr",
                    "ref_id": "b4",
                    "text": "[5]"
                },
                {
                    "start": 6,
                    "end": 9,
                    "type": "bibr",
                    "ref_id": "b5",
                    "text": "[6]"
                },
                {
                    "start": 9,
                    "end": 12,
                    "type": "bibr",
                    "ref_id": "b8",
                    "text": "[9]"
                },
                {
                    "start": 12,
                    "end": 16,
                    "type": "bibr",
                    "ref_id": "b9",
                    "text": "[10]"
                },
                {
                    "start": 16,
                    "end": 20,
                    "type": "bibr",
                    "ref_id": "b10",
                    "text": "[11]"
                },
                {
                    "start": 20,
                    "end": 23,
                    "type": "bibr",
                    "ref_id": "b12",
                    "text": "13,"
                },
                {
                    "start": 23,
                    "end": 25,
                    "type": "bibr",
                    "ref_id": "b13",
                    "text": "14"
                },
                {
                    "start": 63,
                    "end": 66,
                    "type": "bibr",
                    "ref_id": "b9",
                    "text": "10,"
                },
                {
                    "start": 66,
                    "end": 69,
                    "type": "bibr",
                    "ref_id": "b12",
                    "text": "13,"
                },
                {
                    "start": 69,
                    "end": 71,
                    "type": "bibr",
                    "ref_id": "b13",
                    "text": "14"
                }
            ]
        },
        {
            "text": "We believe that less stinging occurred because of pH differences between medications (dorzolamide/timolol pH =5.6, brinzolamide/timolol pH =7.2). ",
            "section": "Clinical Ophthalmology"
        },
        {
            "text": "The frequency of blurred vision in the DTFC group was not significantly different from that observed in the BTFC group. ",
            "section": "Clinical Ophthalmology"
        },
        {
            "text": "This is in agreement with one previous study, 13 but two other studies 10,14 found that BTFC drops caused blurred vision more often than DTFC drops. ",
            "section": "Clinical Ophthalmology",
            "ref_spans": [
                {
                    "start": 46,
                    "end": 48,
                    "type": "bibr",
                    "ref_id": "b12",
                    "text": "13"
                },
                {
                    "start": 71,
                    "end": 74,
                    "type": "bibr",
                    "ref_id": "b9",
                    "text": "10,"
                },
                {
                    "start": 74,
                    "end": 76,
                    "type": "bibr",
                    "ref_id": "b13",
                    "text": "14"
                }
            ]
        },
        {
            "text": "BTFC drops are a liquid suspension, which is known to cause blurred vision. ",
            "section": "Clinical Ophthalmology"
        },
        {
            "text": "In a previous study, 79.2% of patients preferred BTFC drops over DTFC drops. ",
            "section": "Clinical Ophthalmology"
        },
        {
            "text": "14 Likewise, Lanzl and Raber 9 reported that patients preferred BTFC drop (82.0%) significantly more often than they preferred DTFC drops (8.8%). ",
            "section": "Clinical Ophthalmology",
            "ref_spans": [
                {
                    "start": 0,
                    "end": 2,
                    "type": "bibr",
                    "ref_id": "b13",
                    "text": "14"
                }
            ]
        },
        {
            "text": "We found that 33.3% of our participants preferred using DTFC drops and that 27.3% of our participants preferred using BTFC drops. ",
            "section": "Clinical Ophthalmology"
        },
        {
            "text": "The reason cited for preferring DTFC was less vision blurring. ",
            "section": "Clinical Ophthalmology"
        },
        {
            "text": "Participants preferred BTFC drops because they caused less stinging. ",
            "section": "Clinical Ophthalmology"
        },
        {
            "text": "Consequently, we considered the importance of sensation in determining patient preference.",
            "section": "Clinical Ophthalmology"
        },
        {
            "text": "In conclusion, we found no significant difference in IOP, subject compliance, or blurred vision in participants who switched from DTFC drops to BTFC drops. ",
            "section": "Clinical Ophthalmology"
        },
        {
            "text": "However, stinging was reported more frequently during treatment with DTFC drops. ",
            "section": "Clinical Ophthalmology"
        },
        {
            "text": "Therefore, in patients who experience stinging with the administration of DTFC drops, switching to BTFC drops is an acceptable glaucoma treatment option.",
            "section": "Clinical Ophthalmology"
        },
        {
            "text": "No author has any conflicts of interest to declare that is relevant to the subject of this article.",
            "section": "Disclosure"
        }
    ]
}